NCT06712836View on ClinicalTrials.gov

A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions
ObesityOverweight or Obesity
Interventions
DRUG

MET097

MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.

DRUG

Placebo

Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.

Trial Locations (2)

33024

Research Site MET097 24-201-002, Hollywood

92801

Research Site MET097 24-201-001, Anaheim

Sponsors

Lead Sponsor

Metsera
All Listed Sponsors
lead

Metsera

INDUSTRY